Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · ARK Invest

ARK Genomic Revolution ETF (ARKG)

Ticker ARKG · · Holdings as of Jul 31, 2026

Expense ratio
0.75%$75/yr per $10k
5-yr return
−6.5%annualized
1-yr return
−28.1%as of Dec 2024
Net assets
$1.6Ball share classes
Holdings
33

Bottom line

Is ARKG a good fund? The bottom line

ARKG is an actively managed health care sector ETF from ARK Invest.

It charges 0.75% — about $75 a year on every $10,000 invested, cheaper than 66% of health care sector funds we track.

It returned −28.1% over one year, −6.5% a year over five years, +1.9% a year over ten (as of Dec 31, 2024, per its prospectus).

With $1.6 billion in net assets and 33 holdings, its largest position is 10x Genomics Inc (9.4%) and the top 10 make up 59.1% of the portfolio.

What to watch

  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 59.1% of assets

Updated Nov 19, 2026

What ARKG invests in

The ARK Genomic Revolution ETFs (Fund) investment objective is long -term growth of capital.

The Fund is an actively -managed exchange -traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Funds investment theme of the genomics* revolution (Genomics Revolution Companies), which is described below: Genomic Revolution Companies. Companies that the Adviser believes are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing,** analysis, synthesis or instrumentation.…

From the fund's prospectus (filed Nov 26, 2025).

ARKG performance

Fund calendar-year total returns, 2015–2024 2015: −1.5%; 2016: −18.4%; 2017: +45.4%; 2018: +0.6%; 2019: +43.8%; 2020: +180.5%; 2021: −33.9%; 2022: −53.9%; 2023: +16.2%; 2024: −28.1% −2% 2015 −18% 2016 +45% 2017 +1% 2018 +44% 2019 +181% 2020 −34% 2021 −54% 2022 +16% 2023 −28% 2024
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
ARKG−28.1%−6.5%+1.9%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2024

Full ARKG performance history →

What ARKG costs

On a $10,000 investment, ARKG's 0.75% expense ratio costs about $75 a year. The prospectus estimates $930 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full ARKG fee table →

ARKG top 10 holdings

#Holding% of fund
110x Genomics Inc TXG9.39%
2Twist Bioscience Corp TWST7.73%
3Tempus Ai Inc TEM6.56%
4Crispr Therapeutics Ag CRSP6.29%
5Personalis Inc PSNL5.47%
6Absci Corp ABSI5.14%
7Guardant Health Inc GH4.74%
8Illumina Inc ILMN4.74%
9Eli Lilly & Company LLY4.68%
10Caredx Inc CDNA4.30%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 59.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to ARKG

More funds like ARKG →

ARKG FAQ

What is the expense ratio of ARKG?
ARKG's expense ratio is 0.75%, which works out to about $75 a year for every $10,000 invested. The prospectus estimates total costs of $930 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is ARKG a good investment?
It depends on your goals, but the data points to: 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 59.1% of assets. This is general information, not personalized advice.
What does ARKG hold?
ARKG's largest holdings are 10x Genomics Inc (9.4%), Twist Bioscience Corp (7.7%), Tempus Ai Inc (6.6%), Crispr Therapeutics Ag (6.3%), Personalis Inc (5.5%). It holds 33 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is ARKG's 5-year return?
ARKG returned −6.5% a year over the five years ending Dec 31, 2024, and +1.9% a year over ten years. Past performance does not guarantee future results.
Who manages ARKG?
ARKG is offered by ARK Invest through ARK ETF Trust.